AIM ImmunoTech Inc. (0A4Y)
LSE
Closed
Aug 25, 2026
Day's Range
0.249952 wk Range
0.2226Overview - 0A4Y - AIM ImmunoTech Inc.
Key Statistics
Valuation
Enterprise Value
2.06M
P/E (Trailing)
‪7.73‬
Price / Book
‪0.99‬
EV / EBITDA
‪-0.19‬
Profitability
Profit Margin
‪19.75%‬
Operating Margin
‪-13,511.53%‬
Return on Assets
‪-82.57%‬
Return on Equity
‪-2,382.30%‬
Ownership
Shares Outstanding
101.97M
Float
27.68M
Held by Insiders
‪0.53%‬
Held by Institutions
‪3.87%‬
Price stats
Beta
‪1.19‬
50-Day Avg
‪0.4790‬
200-Day Avg
‪0.5130‬
Peers - 0A4Y - AIM ImmunoTech Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0A4YLSEAIM ImmunoTech Inc.-875.01%52-week change7.73P/E (Trailing)‪19.75%‬Profit Margin
- 0A45LSEModerna, Inc.+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0RU5LSEOncoinvent ASA+98.28%52-week change292.50P/E (Trailing)‪34.25%‬Profit Margin
- 0GQULSEActive Biotech AB (publ)+96.66%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0T6GLSEQ32 Bio Inc.+87.72%52-week change—P/E (Trailing)‪62.87%‬Profit Margin
- 0RISLSECircio Holding ASA+94.34%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0NWKLSEValerio Tx Corp.+91.70%52-week change1.81P/E (Trailing)‪-190.36%‬Profit Margin
Profile Summary - 0A4Y - AIM ImmunoTech Inc.
About
AIM ImmunoTech Inc. is a biotechnology and immuno-pharmaceutical company specializing in the development of novel therapeutics for multiple cancers, immune disorders, and viral infections including COVID-19. Its flagship product, Ampligen®, is an RNA-based immuno-modulatory drug with broad-spectrum activity, currently…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
